Characteristics and Outcomes of Myelodysplastic Syndrome Patients Treated With Darbepoetin Alfa for Anemia in Turkey: A Multicenter Retrospective Study

被引：0
|
作者：
Acar, Ibrahim Halil [1 ]
Atalay, Figen [2 ]
Demirsoy, Esra Terzi [3 ]
Can, Ferda [4 ]
Guven, Zeynep Tugba [5 ]
Cetiner, Mustafa [6 ]
Tombak, Anil [7 ]
Comert, Melda [8 ]
Guvenc, Birol [1 ]
机构：
[1] Cukurova Univ, Dept Hematol, Dept Internal Med, Fac Med, Adana, Turkiye
[2] Baskent Univ, Istanbul Hosp, Hematol Clin, Ankara, Turkiye
[3] SBU Kocaeli Derince Training & Res Hosp, Hematol Clin, Kocaeli, Turkiye
[4] Ankara City Hosp, Hematol Clin, Ankara, Turkiye
[5] Erciyes Univ, Dept Hematol, Dept Internal Med, Fac Med, Kayseri, Turkiye
[6] Acibadem Maslak Hosp, Hematol Clin, Istanbul, Turkiye
[7] Mersin Univ, Dept Hematol, Dept Internal Med, Fac Med, Mersin, Turkiye
[8] SBU Gulhane Training & Res Hosp, Hematol Clin, Istanbul, Turkiye
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
MDS; myelodysplastic syndrome; darbepoetin alfa;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-143
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [1] Darbepoetin alfa for anemia with myelodysplastic syndrome
    Seastone, David J.
    Gerds, Aaron T.
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (02) : 139 - 146
  • [2] Darbepoetin alfa for the treatment of anemia in patients with myelodysplastic syndrome.
    Giraldo, P
    Nomdedeu, B
    Loscertales, J
    Requena, C
    de Paz, R
    Tormo, M
    Navarro, P
    Benedit, P
    Gasquet, JA
    BLOOD, 2005, 106 (11) : 714A - 714A
  • [3] Effectiveness of darbepoetin alfa vs epoetin alfa in patients with anemia resulting from myelodysplastic syndrome (MDS): results of a retrospective cohort study.
    Patten, JE
    Sullivan, T
    Mun, Y
    Wallace, J
    PHARMACOTHERAPY, 2005, 25 (03): : 468 - 468
  • [4] Retrospective study of the appropriate utilization of epoetin alfa and darbepoetin alfa in cancer patients with anemia
    Wong, SF
    Brown, ML
    Sarkisian, R
    PHARMACOTHERAPY, 2004, 24 (10): : 1452 - 1452
  • [5] A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
    Schwartzberg, L
    Shiffman, R
    Tomita, D
    Stolshek, B
    Rossi, G
    Adamson, R
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2781 - 2796
  • [6] Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: A retrospective cohort study
    Nurko, Saul
    Spirko, Rita
    Law, Amy
    Dennis, Vincent W.
    CLINICAL THERAPEUTICS, 2007, 29 (09) : 2010 - 2021
  • [7] Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa.
    Fahrbach, KR
    Frame, D
    Scheye, R
    Fastenau, JM
    Drielick, M
    Piech, CT
    Nalysnyk, L
    BLOOD, 2003, 102 (11) : 510B - 511B
  • [8] Epoetin alfa and darbepoetin alfa anemia treatment outcomes in cancer patients from a VA perspective
    Papatheofanis, FJ
    Fastenau, JM
    Chiang, T
    Piech, CT
    VALUE IN HEALTH, 2004, 7 (03) : 246 - 246
  • [9] Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
    Abaza, Yasmin
    Xie, Zhuoer
    Burkart, Madelyn
    Badar, Talha
    Desai, Pinkal
    Shallis, Rory M.
    Patel, Anand Ashwin
    Cohen-Nowak, Adam
    Oh, Timothy S.
    Walker, Chelsea
    Easwar, Neela
    Kewan, Tariq
    Cannova, Joseph
    Bell-Burdett, Kirsten
    Al Ali, Najla H.
    Sallman, David A.
    Roboz, Gail J.
    Carraway, Hetty E.
    Zeidan, Amer M.
    Patnaik, Mrinal M.
    Altman, Jessica K.
    Komrokji, Rami S.
    BLOOD, 2023, 142
  • [10] Hematologic outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients with anemia: results of the Dosing and Outcomes Study of Erythropoiesis Stimulating Therapies (DOSE Registry).
    Memisoglu, A
    Peake, C
    Vichare, R
    McKenzie, RS
    Howell, J
    Piech, CT
    PHARMACOTHERAPY, 2005, 25 (10): : 1469 - 1469
12345